CDK4 and myalgic encephalomeyelitis/chronic fatigue syndrome: Survival outcomes by CDK4/6i in the exclusive first-line treatment group appear to show a similar tendency; with palbociclib and abemaciclib, respectively, the 3-year rwPFS rate was 47.6% and 54.2% (Supplementary Fig. 1 A, B), the 3-year CFS rate was 58.8% and 60.4% (Supplementary Fig. 2 A, B), and the 3-year OS rate was 85.8% and 80.6% (Supplementary Fig. 3 A, B).